8 sources checked · Left, Center, and Right included · 47m ago
Different Spin
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
CNBC and Fox Business - Latest describe the same event in different terms.
2 Left4 Center2 Right
Same story. Different framing.Left, center, and right outlets are covering the same event. Here’s how each side worded it.
DIFFERENT SPIN
HOW EACH SIDE WORDED IT
Left-leaningCenter-leftFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, ZepboundCNBCMostly Factual
vs
Right-leaningFDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision lossFox Business - LatestMixed
Center baseline · The Plain Dealer (Cleveland.com)HighOzempic, Wegovy and Zepbound get new FDA warning over rare condition
As of November 10, 2026 at 2:43 PM, this is how Optics News reads the wording differences in this story.
What happenedThe FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision loss.
The headline splitThe left frames it as "FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound". The right frames it as "FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss".
Match confidenceHigh confidence. 8 sources checked, Left/Center/Right all represented. Best read as a clear framing signal — not a fact-check.
Same-event confidenceHigh
8 sources across Left, Center, and Right all describe the same event.
Framing confidenceModerate
75/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftFDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
CNBC · Center-left · News report
CenterOzempic, Wegovy and Zepbound get new FDA warning over rare condition
The Plain Dealer (Cleveland.com) · Center · News report
Right / center-rightOzempic, Wegovy and Zepbound get new FDA warning over rare condition
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
Ozempic, Wegovy and Zepbound get new FDA warning over rare condition
The FDA is requiring new warnings for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound over a potential increased risk of a rare eye condition that can cause permanent vision lo...
